+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Bradykinin Receptor Antagonists Market - Global Forecast 2026-2032- Product Image
Bradykinin Receptor Antagonists Market - Global Forecast 2026-2032- Product Image
Sale

Bradykinin Receptor Antagonists Market - Global Forecast 2026-2032

  • Report

  • 191 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6085096
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Bradykinin Receptor Antagonists Market is projected to reach USD 230.99 Million in 2026. It is expected to continue growing at a CAGR of 14.37%, reaching USD 525.45 Million by 2032.

Bradykinin Receptor Antagonists: Executive Overview

Bradykinin receptor antagonists are medicines designed to counteract signaling associated with bradykinin, a peptide involved in vascular permeability, inflammation, pain, and blood-pressure regulation. Their most established clinical relevance is in bradykinin-mediated angioedema, where excessive signaling can cause potentially life-threatening swelling of the skin, gastrointestinal tract, or upper airway. The therapeutic landscape is shaped by disease recognition, emergency-care pathways, diagnostic differentiation from histamine-mediated reactions, regulatory requirements, and access to specialist treatment.

Clinical value depends on rapid administration, appropriate patient selection, and continuity of care after acute episodes. Evidence generation is therefore focused not only on symptom control but also on onset of action, safety, repeat-use practicality, pediatric and hereditary disease populations, and integration into emergency and home-treatment protocols.

From Emergency Rescue to Integrated Bradykinin-Disorder Management

The landscape is shifting from isolated emergency intervention toward structured management of recurrent and hereditary bradykinin-mediated disorders. Greater awareness of the distinction between histamine-mediated allergy and bradykinin-mediated angioedema is improving treatment selection, while multidisciplinary pathways increasingly connect emergency departments, immunology, allergy, primary care, and patient self-management.

Additional change is coming from administration convenience and care setting. Products and protocols that support rapid use outside hospitals may reduce delays, but implementation requires patient education, clear action plans, reliable supply, and clinician confidence. Regulatory scrutiny remains centered on clinically meaningful response, safety in repeated exposure, use in vulnerable populations, and consistency of evidence across different forms of angioedema.

Artificial Intelligence Is Strengthening Diagnosis, Trial Design, and Care Coordination

Artificial intelligence can support the bradykinin receptor antagonist field by identifying patterns in electronic health records, emergency presentations, medication histories, and laboratory data that may help distinguish bradykinin-mediated angioedema from other causes. Natural-language processing can surface under-recognized episodes, treatment delays, and recurrent presentations, while clinical decision-support tools may help prioritize airway assessment and specialist referral.

In research, machine-learning methods can improve cohort identification, characterize treatment-response patterns, and help design more efficient studies for rare diseases. These applications require careful validation because coding inconsistencies, limited datasets, and confounding by disease severity can produce misleading conclusions. Human oversight, transparent validation, privacy safeguards, and prospective clinical evaluation remain essential before algorithmic outputs influence treatment decisions.

Regional Insights: Access and Care Pathways Define Adoption Conditions

North America generally benefits from established specialty networks, emergency-care infrastructure, and heightened recognition of hereditary angioedema, although reimbursement requirements and disparities in access can affect timely treatment. Europe’s environment is influenced by coordinated rare-disease initiatives, national health systems, and differing reimbursement decisions across countries. Asia-Pacific combines advanced specialty care in several markets with substantial variation in diagnosis, availability, and patient education.

Latin America faces uneven access to specialist diagnosis, emergency medicines, and confirmatory testing, making distribution reliability and clinician training important priorities. The Middle East is characterized by expanding tertiary-care capacity alongside differences in reimbursement and rare-disease awareness between countries. Africa has significant opportunities to improve recognition and referral, but limited specialist coverage, diagnostic capacity, and medicine availability remain central constraints.

Group Insights: Economic and Policy Blocs Shape Implementation

ASEAN members face varied regulatory systems, healthcare resources, and specialist availability, so regional collaboration on diagnosis, procurement, and clinical education could improve consistency. BRICS countries present broad differences in disease surveillance, reimbursement, domestic manufacturing capacity, and access to advanced emergency care, with local evidence often important for adoption.

The European Union benefits from cross-border research and rare-disease cooperation, while national reimbursement and hospital procurement still influence practical access. G7 systems typically have mature regulatory and clinical infrastructures, but affordability, diagnostic delays, and unequal specialist access remain relevant. GCC countries often combine well-resourced tertiary facilities with a need for coordinated referral pathways and local expertise. NATO members span diverse health systems; preparedness, emergency-care interoperability, and continuity of supply are particularly relevant in cross-border or high-pressure settings.

Country Insights: Diverse Regulatory, Clinical, and Access Priorities

Australia and Canada rely on specialist-led systems in which geographic distance and public reimbursement pathways can affect access. Brazil and Mexico face uneven specialist coverage and regional differences in diagnosis and treatment availability. China and India have large and diverse healthcare systems, with growing capacity but persistent variation between major urban centers and less-served regions. Japan and South Korea combine advanced clinical infrastructure with strong opportunities for standardized rare-disease pathways.

France, Germany, Italy, Spain, and the United Kingdom have substantial expertise in rare diseases, while national assessment, procurement, and reimbursement processes shape real-world availability. Russia’s access environment is influenced by health-system regionalization, regulatory processes, and supply continuity. Across the United States, specialist networks and emergency capabilities support treatment, but insurance conditions, diagnostic confusion, and care fragmentation can still delay appropriate intervention.

Leadership Priorities: Improve Recognition, Readiness, and Evidence Quality

Industry leaders should prioritize clinically validated education that helps emergency clinicians distinguish bradykinin-mediated angioedema from histamine-mediated reactions and recognize airway risk. Treatment pathways should be designed around rapid access, clear escalation criteria, repeat-use planning, and coordinated follow-up with allergy, immunology, and emergency-care teams. Patient-facing materials should use plain language and support confidence in prescribed self-administration where appropriate.

Evidence strategies should include diverse real-world populations, pediatric and recurrent-disease cohorts, patient-reported outcomes, and analyses of time to treatment and healthcare utilization. Access planning should account for reimbursement documentation, hospital formularies, specialty pharmacies, cold-chain or storage requirements where relevant, and regional supply resilience. Responsible use of artificial intelligence should proceed through validated, auditable tools that augment rather than replace clinical judgment.

Methodology: Evidence Triangulation Across Clinical, Policy, and Access Dimensions

This executive summary uses a structured qualitative review framework for bradykinin receptor antagonists. The assessment organizes findings around disease biology, clinical use, regulatory and reimbursement conditions, diagnostic practice, treatment delivery, patient needs, and technology-enabled care. Regional, group, and country comparisons are interpreted as differences in healthcare infrastructure, specialist capacity, policy environment, and implementation conditions rather than as measures of commercial performance.

The approach emphasizes triangulation across peer-reviewed clinical evidence, treatment guidelines, regulatory materials, health-system publications, rare-disease resources, and documented care pathways. Findings are framed cautiously where evidence is heterogeneous or country conditions vary within a geography. No market estimates, market shares, forecasts, or company-specific assessments are used.

Conclusion: Build Faster, Better-Integrated Care for Bradykinin-Mediated Angioedema

The field’s central opportunity is to make correct treatment available earlier and embed it within dependable care pathways. Progress will depend on accurate recognition, emergency readiness, specialist coordination, patient education, and evidence that reflects recurrent disease and diverse healthcare settings. Regional and national differences mean that a single access model will not be sufficient.

Leaders who combine rigorous clinical evidence with practical implementation planning can improve treatment reliability while supporting responsible innovation. Artificial intelligence may add value in case identification, research, and coordination, but only when validated and governed appropriately. Sustained progress ultimately requires alignment among clinicians, patients, regulators, payers, and health systems.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Bradykinin Receptor Antagonists Market, by Type
7.1. Introduction
7.2. Biologic
7.2.1. MAb
7.2.2. Peptide
7.3. Small Molecule
8. Bradykinin Receptor Antagonists Market, by Indication
8.1. Introduction
8.2. Chronic Cough
8.2.1. Idiopathic Cough
8.2.2. Refractory Cough
8.3. Diabetic Nephropathy
8.4. Hereditary Angioedema
8.4.1. Acute Attack
8.4.2. Prophylaxis
9. Bradykinin Receptor Antagonists Market, by Route Of Administration
9.1. Introduction
9.2. Inhalation
9.3. Oral
9.3.1. Capsule
9.3.2. Tablet
9.4. Parenteral
9.4.1. IV
9.4.2. SC
9.5. Topical
10. Bradykinin Receptor Antagonists Market, by End User
10.1. Introduction
10.2. Ambulatory Care
10.2.1. Clinics
10.2.2. Diagnostic Centers
10.3. Home Care
10.3.1. Home Nursing
10.3.2. Self Administration
10.4. Hospital
10.4.1. Private Hospital
10.4.2. Public Hospital
11. Bradykinin Receptor Antagonists Market, by Region
11.1. Introduction
11.2. Asia-Pacific
11.3. North America
11.4. Latin America
11.5. Europe
11.6. Middle East
11.7. Africa
12. Bradykinin Receptor Antagonists Market, by Group
12.1. Introduction
12.2. ASEAN
12.3. GCC
12.4. European Union
12.5. BRICS
12.6. G7
12.7. NATO
13. Bradykinin Receptor Antagonists Market, by Country
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. United Kingdom
13.7. Germany
13.8. France
13.9. Russia
13.10. Italy
13.11. Spain
13.12. China
13.13. India
13.14. Japan
13.15. Australia
13.16. South Korea
14. Competitive Landscape
14.1. Market Share Analysis, 2025
14.2. Market Concentration Analysis, 2025
14.2.1. Concentration Ratio (CR)
14.2.2. Herfindahl Hirschman Index (HHI)
14.3. Recent Developments & Impact Analysis, 2025
14.4. Product Portfolio Analysis, 2025
14.5. Benchmarking Analysis, 2025
15. Company Profiles
15.1. Abbott Laboratories
15.2. Bayer AG
15.3. BioCryst Pharmaceuticals, Inc.
15.4. Boehringer Ingelheim International GmbH
15.5. CSL Limited
15.6. Dyax Corp.
15.7. Elan Pharmaceuticals, Inc.
15.8. Ionis Pharmaceuticals, Inc.
15.9. Jerini AG
15.10. KalVista Pharmaceuticals, Inc.
15.11. Laboratoires Fournier S.A.
15.12. Merck & Co., Inc.
15.13. Novartis AG
15.14. Pfizer Inc.
15.15. Pharming Group N.V.
15.16. Pharvaris N.V.
15.17. Sanofi S.A.
15.18. SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A.
15.19. Swedish Orphan Biovitrum AB
15.20. Takeda Pharmaceutical Company Limited
16. Key Experts
LIST OF FIGURES
FIGURE 1. Global Bradykinin Receptor Antagonists Market, Years Considered for the Study
FIGURE 2. Global Bradykinin Receptor Antagonists Market, Research Design
FIGURE 3. Global Bradykinin Receptor Antagonists Market, Research Framework
FIGURE 4. Global Bradykinin Receptor Antagonists Market, Data Triangulation
FIGURE 5. Global Bradykinin Receptor Antagonists Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Bradykinin Receptor Antagonists Market Size, by Type, 2025 vs 2032 (%)
FIGURE 7. Global Bradykinin Receptor Antagonists Market Size, by Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Bradykinin Receptor Antagonists Market Size, by Indication, 2025 vs 2032 (%)
FIGURE 9. Global Bradykinin Receptor Antagonists Market Size, by Indication, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Bradykinin Receptor Antagonists Market Size, by Route Of Administration, 2025 vs 2032 (%)
FIGURE 11. Global Bradykinin Receptor Antagonists Market Size, by Route Of Administration, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Bradykinin Receptor Antagonists Market Size, by End User, 2025 vs 2032 (%)
FIGURE 13. Global Bradykinin Receptor Antagonists Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Bradykinin Receptor Antagonists Market Size, by Region, 2025 vs 2032 (%)
FIGURE 15. Global Bradykinin Receptor Antagonists Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Bradykinin Receptor Antagonists Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 17. Global Bradykinin Receptor Antagonists Market Size, by Country, 2025 vs 2032 (%)
FIGURE 18. Global Bradykinin Receptor Antagonists Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 19. Global Bradykinin Receptor Antagonists Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Bradykinin Receptor Antagonists Market Segmentation & Coverage
TABLE 2. Global Bradykinin Receptor Antagonists Market Size, 2017-2032 (USD Million)
TABLE 3. Global Bradykinin Receptor Antagonists Market Size, by Type, 2017-2032 (USD Million)
TABLE 4. Global Biologic Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Biologic Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Biologic Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global MAb Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global MAb Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global MAb Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Peptide Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Peptide Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Peptide Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Small Molecule Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Small Molecule Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Small Molecule Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Bradykinin Receptor Antagonists Market Size, by Indication, 2017-2032 (USD Million)
TABLE 17. Global Chronic Cough Market Size, by Region, 2017-2032 (USD Million)
TABLE 18. Global Chronic Cough Market Size, by Group, 2017-2032 (USD Million)
TABLE 19. Global Chronic Cough Market Size, by Country, 2017-2032 (USD Million)
TABLE 20. Global Idiopathic Cough Market Size, by Region, 2017-2032 (USD Million)
TABLE 21. Global Idiopathic Cough Market Size, by Group, 2017-2032 (USD Million)
TABLE 22. Global Idiopathic Cough Market Size, by Country, 2017-2032 (USD Million)
TABLE 23. Global Refractory Cough Market Size, by Region, 2017-2032 (USD Million)
TABLE 24. Global Refractory Cough Market Size, by Group, 2017-2032 (USD Million)
TABLE 25. Global Refractory Cough Market Size, by Country, 2017-2032 (USD Million)
TABLE 26. Global Diabetic Nephropathy Market Size, by Region, 2017-2032 (USD Million)
TABLE 27. Global Diabetic Nephropathy Market Size, by Group, 2017-2032 (USD Million)
TABLE 28. Global Diabetic Nephropathy Market Size, by Country, 2017-2032 (USD Million)
TABLE 29. Global Hereditary Angioedema Market Size, by Region, 2017-2032 (USD Million)
TABLE 30. Global Hereditary Angioedema Market Size, by Group, 2017-2032 (USD Million)
TABLE 31. Global Hereditary Angioedema Market Size, by Country, 2017-2032 (USD Million)
TABLE 32. Global Acute Attack Market Size, by Region, 2017-2032 (USD Million)
TABLE 33. Global Acute Attack Market Size, by Group, 2017-2032 (USD Million)
TABLE 34. Global Acute Attack Market Size, by Country, 2017-2032 (USD Million)
TABLE 35. Global Prophylaxis Market Size, by Region, 2017-2032 (USD Million)
TABLE 36. Global Prophylaxis Market Size, by Group, 2017-2032 (USD Million)
TABLE 37. Global Prophylaxis Market Size, by Country, 2017-2032 (USD Million)
TABLE 38. Global Bradykinin Receptor Antagonists Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 39. Global Inhalation Market Size, by Region, 2017-2032 (USD Million)
TABLE 40. Global Inhalation Market Size, by Group, 2017-2032 (USD Million)
TABLE 41. Global Inhalation Market Size, by Country, 2017-2032 (USD Million)
TABLE 42. Global Oral Market Size, by Region, 2017-2032 (USD Million)
TABLE 43. Global Oral Market Size, by Group, 2017-2032 (USD Million)
TABLE 44. Global Oral Market Size, by Country, 2017-2032 (USD Million)
TABLE 45. Global Capsule Market Size, by Region, 2017-2032 (USD Million)
TABLE 46. Global Capsule Market Size, by Group, 2017-2032 (USD Million)
TABLE 47. Global Capsule Market Size, by Country, 2017-2032 (USD Million)
TABLE 48. Global Tablet Market Size, by Region, 2017-2032 (USD Million)
TABLE 49. Global Tablet Market Size, by Group, 2017-2032 (USD Million)
TABLE 50. Global Tablet Market Size, by Country, 2017-2032 (USD Million)
TABLE 51. Global Parenteral Market Size, by Region, 2017-2032 (USD Million)
TABLE 52. Global Parenteral Market Size, by Group, 2017-2032 (USD Million)
TABLE 53. Global Parenteral Market Size, by Country, 2017-2032 (USD Million)
TABLE 54. Global IV Market Size, by Region, 2017-2032 (USD Million)
TABLE 55. Global IV Market Size, by Group, 2017-2032 (USD Million)
TABLE 56. Global IV Market Size, by Country, 2017-2032 (USD Million)
TABLE 57. Global SC Market Size, by Region, 2017-2032 (USD Million)
TABLE 58. Global SC Market Size, by Group, 2017-2032 (USD Million)
TABLE 59. Global SC Market Size, by Country, 2017-2032 (USD Million)
TABLE 60. Global Topical Market Size, by Region, 2017-2032 (USD Million)
TABLE 61. Global Topical Market Size, by Group, 2017-2032 (USD Million)
TABLE 62. Global Topical Market Size, by Country, 2017-2032 (USD Million)
TABLE 63. Global Bradykinin Receptor Antagonists Market Size, by End User, 2017-2032 (USD Million)
TABLE 64. Global Ambulatory Care Market Size, by Region, 2017-2032 (USD Million)
TABLE 65. Global Ambulatory Care Market Size, by Group, 2017-2032 (USD Million)
TABLE 66. Global Ambulatory Care Market Size, by Country, 2017-2032 (USD Million)
TABLE 67. Global Clinics Market Size, by Region, 2017-2032 (USD Million)
TABLE 68. Global Clinics Market Size, by Group, 2017-2032 (USD Million)
TABLE 69. Global Clinics Market Size, by Country, 2017-2032 (USD Million)
TABLE 70. Global Diagnostic Centers Market Size, by Region, 2017-2032 (USD Million)
TABLE 71. Global Diagnostic Centers Market Size, by Group, 2017-2032 (USD Million)
TABLE 72. Global Diagnostic Centers Market Size, by Country, 2017-2032 (USD Million)
TABLE 73. Global Home Care Market Size, by Region, 2017-2032 (USD Million)
TABLE 74. Global Home Care Market Size, by Group, 2017-2032 (USD Million)
TABLE 75. Global Home Care Market Size, by Country, 2017-2032 (USD Million)
TABLE 76. Global Home Nursing Market Size, by Region, 2017-2032 (USD Million)
TABLE 77. Global Home Nursing Market Size, by Group, 2017-2032 (USD Million)
TABLE 78. Global Home Nursing Market Size, by Country, 2017-2032 (USD Million)
TABLE 79. Global Self Administration Market Size, by Region, 2017-2032 (USD Million)
TABLE 80. Global Self Administration Market Size, by Group, 2017-2032 (USD Million)
TABLE 81. Global Self Administration Market Size, by Country, 2017-2032 (USD Million)
TABLE 82. Global Hospital Market Size, by Region, 2017-2032 (USD Million)
TABLE 83. Global Hospital Market Size, by Group, 2017-2032 (USD Million)
TABLE 84. Global Hospital Market Size, by Country, 2017-2032 (USD Million)
TABLE 85. Global Private Hospital Market Size, by Region, 2017-2032 (USD Million)
TABLE 86. Global Private Hospital Market Size, by Group, 2017-2032 (USD Million)
TABLE 87. Global Private Hospital Market Size, by Country, 2017-2032 (USD Million)
TABLE 88. Global Public Hospital Market Size, by Region, 2017-2032 (USD Million)
TABLE 89. Global Public Hospital Market Size, by Group, 2017-2032 (USD Million)
TABLE 90. Global Public Hospital Market Size, by Country, 2017-2032 (USD Million)
TABLE 91. Global Bradykinin Receptor Antagonists Market Size, by Region, 2017-2032 (USD Million)
TABLE 92. Asia-Pacific Bradykinin Receptor Antagonists Market Size, by Region, 2017-2032 (USD Million)
TABLE 93. Asia-Pacific Bradykinin Receptor Antagonists Market Size, by Type, 2017-2032 (USD Million)
TABLE 94. Asia-Pacific Bradykinin Receptor Antagonists Market Size, by Biologic, 2017-2032 (USD Million)
TABLE 95. Asia-Pacific Bradykinin Receptor Antagonists Market Size, by Indication, 2017-2032 (USD Million)
TABLE 96. Asia-Pacific Bradykinin Receptor Antagonists Market Size, by Chronic Cough, 2017-2032 (USD Million)
TABLE 97. Asia-Pacific Bradykinin Receptor Antagonists Market Size, by Hereditary Angioedema, 2017-2032 (USD Million)
TABLE 98. Asia-Pacific Bradykinin Receptor Antagonists Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 99. Asia-Pacific Bradykinin Receptor Antagonists Market Size, by Oral, 2017-2032 (USD Million)
TABLE 100. Asia-Pacific Bradykinin Receptor Antagonists Market Size, by Parenteral, 2017-2032 (USD Million)
TABLE 101. Asia-Pacific Bradykinin Receptor Antagonists Market Size, by End User, 2017-2032 (USD Million)
TABLE 102. Asia-Pacific Bradykinin Receptor Antagonists Market Size, by Ambulatory Care, 2017-2032 (USD Million)
TABLE 103. Asia-Pacific Bradykinin Receptor Antagonists Market Size, by Home Care, 2017-2032 (USD Million)
TABLE 104. Asia-Pacific Bradykinin Receptor Antagonists Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 105. North America Bradykinin Receptor Antagonists Market Size, by Region, 2017-2032 (USD Million)
TABLE 106. North America Bradykinin Receptor Antagonists Market Size, by Type, 2017-2032 (USD Million)
TABLE 107. North America Bradykinin Receptor Antagonists Market Size, by Biologic, 2017-2032 (USD Million)
TABLE 108. North America Bradykinin Receptor Antagonists Market Size, by Indication, 2017-2032 (USD Million)
TABLE 109. North America Bradykinin Receptor Antagonists Market Size, by Chronic Cough, 2017-2032 (USD Million)
TABLE 110. North America Bradykinin Receptor Antagonists Market Size, by Hereditary Angioedema, 2017-2032 (USD Million)
TABLE 111. North America Bradykinin Receptor Antagonists Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 112. North America Bradykinin Receptor Antagonists Market Size, by Oral, 2017-2032 (USD Million)
TABLE 113. North America Bradykinin Receptor Antagonists Market Size, by Parenteral, 2017-2032 (USD Million)
TABLE 114. North America Bradykinin Receptor Antagonists Market Size, by End User, 2017-2032 (USD Million)
TABLE 115. North America Bradykinin Receptor Antagonists Market Size, by Ambulatory Care, 2017-2032 (USD Million)
TABLE 116. North America Bradykinin Receptor Antagonists Market Size, by Home Care, 2017-2032 (USD Million)
TABLE 117. North America Bradykinin Receptor Antagonists Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 118. Latin America Bradykinin Receptor Antagonists Market Size, by Region, 2017-2032 (USD Million)
TABLE 119. Latin America Bradykinin Receptor Antagonists Market Size, by Type, 2017-2032 (USD Million)
TABLE 120. Latin America Bradykinin Receptor Antagonists Market Size, by Biologic, 2017-2032 (USD Million)
TABLE 121. Latin America Bradykinin Receptor Antagonists Market Size, by Indication, 2017-2032 (USD Million)
TABLE 122. Latin America Bradykinin Receptor Antagonists Market Size, by Chronic Cough, 2017-2032 (USD Million)
TABLE 123. Latin America Bradykinin Receptor Antagonists Market Size, by Hereditary Angioedema, 2017-2032 (USD Million)
TABLE 124. Latin America Bradykinin Receptor Antagonists Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 125. Latin America Bradykinin Receptor Antagonists Market Size, by Oral, 2017-2032 (USD Million)
TABLE 126. Latin America Bradykinin Receptor Antagonists Market Size, by Parenteral, 2017-2032 (USD Million)
TABLE 127. Latin America Bradykinin Receptor Antagonists Market Size, by End User, 2017-2032 (USD Million)
TABLE 128. Latin America Bradykinin Receptor Antagonists Market Size, by Ambulatory Care, 2017-2032 (USD Million)
TABLE 129. Latin America Bradykinin Receptor Antagonists Market Size, by Home Care, 2017-2032 (USD Million)
TABLE 130. Latin America Bradykinin Receptor Antagonists Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 131. Europe Bradykinin Receptor Antagonists Market Size, by Region, 2017-2032 (USD Million)
TABLE 132. Europe Bradykinin Receptor Antagonists Market Size, by Type, 2017-2032 (USD Million)
TABLE 133. Europe Bradykinin Receptor Antagonists Market Size, by Biologic, 2017-2032 (USD Million)
TABLE 134. Europe Bradykinin Receptor Antagonists Market Size, by Indication, 2017-2032 (USD Million)
TABLE 135. Europe Bradykinin Receptor Antagonists Market Size, by Chronic Cough, 2017-2032 (USD Million)
TABLE 136. Europe Bradykinin Receptor Antagonists Market Size, by Hereditary Angioedema, 2017-2032 (USD Million)
TABLE 137. Europe Bradykinin Receptor Antagonists Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 138. Europe Bradykinin Receptor Antagonists Market Size, by Oral, 2017-2032 (USD Million)
TABLE 139. Europe Bradykinin Receptor Antagonists Market Size, by Parenteral, 2017-2032 (USD Million)
TABLE 140. Europe Bradykinin Receptor Antagonists Market Size, by End User, 2017-2032 (USD Million)
TABLE 141. Europe Bradykinin Receptor Antagonists Market Size, by Ambulatory Care, 2017-2032 (USD Million)
TABLE 142. Europe Bradykinin Receptor Antagonists Market Size, by Home Care, 2017-2032 (USD Million)
TABLE 143. Europe Bradykinin Receptor Antagonists Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 144. Middle East Bradykinin Receptor Antagonists Market Size, by Region, 2017-2032 (USD Million)
TABLE 145. Middle East Bradykinin Receptor Antagonists Market Size, by Type, 2017-2032 (USD Million)
TABLE 146. Middle East Bradykinin Receptor Antagonists Market Size, by Biologic, 2017-2032 (USD Million)
TABLE 147. Middle East Bradykinin Receptor Antagonists Market Size, by Indication, 2017-2032 (USD Million)
TABLE 148. Middle East Bradykinin Receptor Antagonists Market Size, by Chronic Cough, 2017-2032 (USD Million)
TABLE 149. Middle East Bradykinin Receptor Antagonists Market Size, by Hereditary Angioedema, 2017-2032 (USD Million)
TABLE 150. Middle East Bradykinin Receptor Antagonists Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 151. Middle East Bradykinin Receptor Antagonists Market Size, by Oral, 2017-2032 (USD Million)
TABLE 152. Middle East Bradykinin Receptor Antagonists Market Size, by Parenteral, 2017-2032 (USD Million)
TABLE 153. Middle East Bradykinin Receptor Antagonists Market Size, by End User, 2017-2032 (USD Million)
TABLE 154. Middle East Bradykinin Receptor Antagonists Market Size, by Ambulatory Care, 2017-2032 (USD Million)
TABLE 155. Middle East Bradykinin Receptor Antagonists Market Size, by Home Care, 2017-2032 (USD Million)
TABLE 156. Middle East Bradykinin Receptor Antagonists Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 157. Africa Bradykinin Receptor Antagonists Market Size, by Region, 2017-2032 (USD Million)
TABLE 158. Africa Bradykinin Receptor Antagonists Market Size, by Type, 2017-2032 (USD Million)
TABLE 159. Africa Bradykinin Receptor Antagonists Market Size, by Biologic, 2017-2032 (USD Million)
TABLE 160. Africa Bradykinin Receptor Antagonists Market Size, by Indication, 2017-2032 (USD Million)
TABLE 161. Africa Bradykinin Receptor Antagonists Market Size, by Chronic Cough, 2017-2032 (USD Million)
TABLE 162. Africa Bradykinin Receptor Antagonists Market Size, by Hereditary Angioedema, 2017-2032 (USD Million)
TABLE 163. Africa Bradykinin Receptor Antagonists Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 164. Africa Bradykinin Receptor Antagonists Market Size, by Oral, 2017-2032 (USD Million)
TABLE 165. Africa Bradykinin Receptor Antagonists Market Size, by Parenteral, 2017-2032 (USD Million)
TABLE 166. Africa Bradykinin Receptor Antagonists Market Size, by End User, 2017-2032 (USD Million)
TABLE 167. Africa Bradykinin Receptor Antagonists Market Size, by Ambulatory Care, 2017-2032 (USD Million)
TABLE 168. Africa Bradykinin Receptor Antagonists Market Size, by Home Care, 2017-2032 (USD Million)
TABLE 169. Africa Bradykinin Receptor Antagonists Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 170. Global Bradykinin Receptor Antagonists Market Size, by Group, 2017-2032 (USD Million)
TABLE 171. ASEAN Bradykinin Receptor Antagonists Market Size, by Group, 2017-2032 (USD Million)
TABLE 172. ASEAN Bradykinin Receptor Antagonists Market Size, by Type, 2017-2032 (USD Million)
TABLE 173. ASEAN Bradykinin Receptor Antagonists Market Size, by Biologic, 2017-2032 (USD Million)
TABLE 174. ASEAN Bradykinin Receptor Antagonists Market Size, by Indication, 2017-2032 (USD Million)
TABLE 175. ASEAN Bradykinin Receptor Antagonists Market Size, by Chronic Cough, 2017-2032 (USD Million)
TABLE 176. ASEAN Bradykinin Receptor Antagonists Market Size, by Hereditary Angioedema, 2017-2032 (USD Million)
TABLE 177. ASEAN Bradykinin Receptor Antagonists Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 178. ASEAN Bradykinin Receptor Antagonists Market Size, by Oral, 2017-2032 (USD Million)
TABLE 179. ASEAN Bradykinin Receptor Antagonists Market Size, by Parenteral, 2017-2032 (USD Million)
TABLE 180. ASEAN Bradykinin Receptor Antagonists Market Size, by End User, 2017-2032 (USD Million)
TABLE 181. ASEAN Bradykinin Receptor Antagonists Market Size, by Ambulatory Care, 2017-2032 (USD Million)
TABLE 182. ASEAN Bradykinin Receptor Antagonists Market Size, by Home Care, 2017-2032 (USD Million)
TABLE 183. ASEAN Bradykinin Receptor Antagonists Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 184. GCC Bradykinin Receptor Antagonists Market Size, by Group, 2017-2032 (USD Million)
TABLE 185. GCC Bradykinin Receptor Antagonists Market Size, by Type, 2017-2032 (USD Million)
TABLE 186. GCC Bradykinin Receptor Antagonists Market Size, by Biologic, 2017-2032 (USD Million)
TABLE 187. GCC Bradykinin Receptor Antagonists Market Size, by Indication, 2017-2032 (USD Million)
TABLE 188. GCC Bradykinin Receptor Antagonists Market Size, by Chronic Cough, 2017-2032 (USD Million)
TABLE 189. GCC Bradykinin Receptor Antagonists Market Size, by Hereditary Angioedema, 2017-2032 (USD Million)
TABLE 190. GCC Bradykinin Receptor Antagonists Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 191. GCC Bradykinin Receptor Antagonists Market Size, by Oral, 2017-2032 (USD Million)
TABLE 192. GCC Bradykinin Receptor Antagonists Market Size, by Parenteral, 2017-2032 (USD Million)
TABLE 193. GCC Bradykinin Receptor Antagonists Market Size, by End User, 2017-2032 (USD Million)
TABLE 194. GCC Bradykinin Receptor Antagonists Market Size, by Ambulatory Care, 2017-2032 (USD Million)
TABLE 195. GCC Bradykinin Receptor Antagonists Market Size, by Home Care, 2017-2032 (USD Million)
TABLE 196. GCC Bradykinin Receptor Antagonists Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 197. European Union Bradykinin Receptor Antagonists Market Size, by Group, 2017-2032 (USD Million)
TABLE 198. European Union Bradykinin Receptor Antagonists Market Size, by Type, 2017-2032 (USD Million)
TABLE 199. European Union Bradykinin Receptor Antagonists Market Size, by Biologic, 2017-2032 (USD Million)
TABLE 200. European Union Bradykinin Receptor Antagonists Market Size, by Indication, 2017-2032 (USD Million)
TABLE 201. European Union Bradykinin Receptor Antagonists Market Size, by Chronic Cough, 2017-2032 (USD Million)
TABLE 202. European Union Bradykinin Receptor Antagonists Market Size, by Hereditary Angioedema, 2017-2032 (USD Million)
TABLE 203. European Union Bradykinin Receptor Antagonists Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 204. European Union Bradykinin Receptor Antagonists Market Size, by Oral, 2017-2032 (USD Million)
TABLE 205. European Union Bradykinin Receptor Antagonists Market Size, by Parenteral, 2017-2032 (USD Million)
TABLE 206. European Union Bradykinin Receptor Antagonists Market Size, by End User, 2017-2032 (USD Million)
TABLE 207. European Union Bradykinin Receptor Antagonists Market Size, by Ambulatory Care, 2017-2032 (USD Million)
TABLE 208. European Union Bradykinin Receptor Antagonists Market Size, by Home Care, 2017-2032 (USD Million)
TABLE 209. European Union Bradykinin Receptor Antagonists Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 210. BRICS Bradykinin Receptor Antagonists Market Size, by Group, 2017-2032 (USD Million)
TABLE 211. BRICS Bradykinin Receptor Antagonists Market Size, by Type, 2017-2032 (USD Million)
TABLE 212. BRICS Bradykinin Receptor Antagonists Market Size, by Biologic, 2017-2032 (USD Million)
TABLE 213. BRICS Bradykinin Receptor Antagonists Market Size, by Indication, 2017-2032 (USD Million)
TABLE 214. BRICS Bradykinin Receptor Antagonists Market Size, by Chronic Cough, 2017-2032 (USD Million)
TABLE 215. BRICS Bradykinin Receptor Antagonists Market Size, by Hereditary Angioedema, 2017-2032 (USD Million)
TABLE 216. BRICS Bradykinin Receptor Antagonists Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 217. BRICS Bradykinin Receptor Antagonists Market Size, by Oral, 2017-2032 (USD Million)
TABLE 218. BRICS Bradykinin Receptor Antagonists Market Size, by Parenteral, 2017-2032 (USD Million)
TABLE 219. BRICS Bradykinin Receptor Antagonists Market Size, by End User, 2017-2032 (USD Million)
TABLE 220. BRICS Bradykinin Receptor Antagonists Market Size, by Ambulatory Care, 2017-2032 (USD Million)
TABLE 221. BRICS Bradykinin Receptor Antagonists Market Size, by Home Care, 2017-2032 (USD Million)
TABLE 222. BRICS Bradykinin Receptor Antagonists Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 223. G7 Bradykinin Receptor Antagonists Market Size, by Group, 2017-2032 (USD Million)
TABLE 224. G7 Bradykinin Receptor Antagonists Market Size, by Type, 2017-2032 (USD Million)
TABLE 225. G7 Bradykinin Receptor Antagonists Market Size, by Biologic, 2017-2032 (USD Million)
TABLE 226. G7 Bradykinin Receptor Antagonists Market Size, by Indication, 2017-2032 (USD Million)
TABLE 227. G7 Bradykinin Receptor Antagonists Market Size, by Chronic Cough, 2017-2032 (USD Million)
TABLE 228. G7 Bradykinin Receptor Antagonists Market Size, by Hereditary Angioedema, 2017-2032 (USD Million)
TABLE 229. G7 Bradykinin Receptor Antagonists Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 230. G7 Bradykinin Receptor Antagonists Market Size, by Oral, 2017-2032 (USD Million)
TABLE 231. G7 Bradykinin Receptor Antagonists Market Size, by Parenteral, 2017-2032 (USD Million)
TABLE 232. G7 Bradykinin Receptor Antagonists Market Size, by End User, 2017-2032 (USD Million)
TABLE 233. G7 Bradykinin Receptor Antagonists Market Size, by Ambulatory Care, 2017-2032 (USD Million)
TABLE 234. G7 Bradykinin Receptor Antagonists Market Size, by Home Care, 2017-2032 (USD Million)
TABLE 235. G7 Bradykinin Receptor Antagonists Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 236. NATO Bradykinin Receptor Antagonists Market Size, by Group, 2017-2032 (USD Million)
TABLE 237. NATO Bradykinin Receptor Antagonists Market Size, by Type, 2017-2032 (USD Million)
TABLE 238. NATO Bradykinin Receptor Antagonists Market Size, by Biologic, 2017-2032 (USD Million)
TABLE 239. NATO Bradykinin Receptor Antagonists Market Size, by Indication, 2017-2032 (USD Million)
TABLE 240. NATO Bradykinin Receptor Antagonists Market Size, by Chronic Cough, 2017-2032 (USD Million)
TABLE 241. NATO Bradykinin Receptor Antagonists Market Size, by Hereditary Angioedema, 2017-2032 (USD Million)
TABLE 242. NATO Bradykinin Receptor Antagonists Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 243. NATO Bradykinin Receptor Antagonists Market Size, by Oral, 2017-2032 (USD Million)
TABLE 244. NATO Bradykinin Receptor Antagonists Market Size, by Parenteral, 2017-2032 (USD Million)
TABLE 245. NATO Bradykinin Receptor Antagonists Market Size, by End User, 2017-2032 (USD Million)
TABLE 246. NATO Bradykinin Receptor Antagonists Market Size, by Ambulatory Care, 2017-2032 (USD Million)
TABLE 247. NATO Bradykinin Receptor Antagonists Market Size, by Home Care, 2017-2032 (USD Million)
TABLE 248. NATO Bradykinin Receptor Antagonists Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 249. Global Bradykinin Receptor Antagonists Market Size, by Country, 2017-2032 (USD Million)
TABLE 250. United States Bradykinin Receptor Antagonists Market Size, 2017-2032 (USD Million)
TABLE 251. United States Bradykinin Receptor Antagonists Market Size, by Type, 2017-2032 (USD Million)
TABLE 252. United States Bradykinin Receptor Antagonists Market Size, by Biologic, 2017-2032 (USD Million)
TABLE 253. United States Bradykinin Receptor Antagonists Market Size, by Indication, 2017-2032 (USD Million)
TABLE 254. United States Bradykinin Receptor Antagonists Market Size, by Chronic Cough, 2017-2032 (USD Million)
TABLE 255. United States Bradykinin Receptor Antagonists Market Size, by Hereditary Angioedema, 2017-2032 (USD Million)
TABLE 256. United States Bradykinin Receptor Antagonists Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 257. United States Bradykinin Receptor Antagonists Market Size, by Oral, 2017-2032 (USD Million)
TABLE 258. United States Bradykinin Receptor Antagonists Market Size, by Parenteral, 2017-2032 (USD Million)
TABLE 259. United States Bradykinin Receptor Antagonists Market Size, by End User, 2017-2032 (USD Million)
TABLE 260. United States Bradykinin Receptor Antagonists Market Size, by Ambulatory Care, 2017-2032 (USD Million)
TABLE 261. United States Bradykinin Receptor Antagonists Market Size, by Home Care, 2017-2032 (USD Million)
TABLE 262. United States Bradykinin Receptor Antagonists Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 263. Canada Bradykinin Receptor Antagonists Market Size, 2017-2032 (USD Million)
TABLE 264. Canada Bradykinin Receptor Antagonists Market Size, by Type, 2017-2032 (USD Million)
TABLE 265. Canada Bradykinin Receptor Antagonists Market Size, by Biologic, 2017-2032 (USD Million)
TABLE 266. Canada Bradykinin Receptor Antagonists Market Size, by Indication, 2017-2032 (USD Million)
TABLE 267. Canada Bradykinin Receptor Antagonists Market Size, by Chronic Cough, 2017-2032 (USD Million)
TABLE 268. Canada Bradykinin Receptor Antagonists Market Size, by Hereditary Angioedema, 2017-2032 (USD Million)
TABLE 269. Canada Bradykinin Receptor Antagonists Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 270. Canada Bradykinin Receptor Antagonists Market Size, by Oral, 2017-2032 (USD Million)
TABLE 271. Canada Bradykinin Receptor Antagonists Market Size, by Parenteral, 2017-2032 (USD Million)
TABLE 272. Canada Bradykinin Receptor Antagonists Market Size, by End User, 2017-2032 (USD Million)
TABLE 273. Canada Bradykinin Receptor Antagonists Market Size, by Ambulatory Care, 2017-2032 (USD Million)
TABLE 274. Canada Bradykinin Receptor Antagonists Market Size, by Home Care, 2017-2032 (USD Million)
TABLE 275. Canada Bradykinin Receptor Antagonists Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 276. Mexico Bradykinin Receptor Antagonists Market Size, 2017-2032 (USD Million)
TABLE 277. Mexico Bradykinin Receptor Antagonists Market Size, by Type, 2017-2032 (USD Million)
TABLE 278. Mexico Bradykinin Receptor Antagonists Market Size, by Biologic, 2017-2032 (USD Million)
TABLE 279. Mexico Bradykinin Receptor Antagonists Market Size, by Indication, 2017-2032 (USD Million)
TABLE 280. Mexico Bradykinin Receptor Antagonists Market Size, by Chronic Cough, 2017-2032 (USD Million)
TABLE 281. Mexico Bradykinin Receptor Antagonists Market Size, by Hereditary Angioedema, 2017-2032 (USD Million)
TABLE 282. Mexico Bradykinin Receptor Antagonists Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 283. Mexico Bradykinin Receptor Antagonists Market Size, by Oral, 2017-2032 (USD Million)
TABLE 284. Mexico Bradykinin Receptor Antagonists Market Size, by Parenteral, 2017-2032 (USD Million)
TABLE 285. Mexico Bradykinin Receptor Antagonists Market Size, by End User, 2017-2032 (USD Million)
TABLE 286. Mexico Bradykinin Receptor Antagonists Market Size, by Ambulatory Care, 2017-2032 (USD Million)
TABLE 287. Mexico Bradykinin Receptor Antagonists Market Size, by Home Care, 2017-2032 (USD Million)
TABLE 288. Mexico Bradykinin Receptor Antagonists Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 289. Brazil Bradykinin Receptor Antagonists Market Size, 2017-2032 (USD Million)
TABLE 290. Brazil Bradykinin Receptor Antagonists Market Size, by Type, 2017-2032 (USD Million)
TABLE 291. Brazil Bradykinin Receptor Antagonists Market Size, by Biologic, 2017-2032 (USD Million)
TABLE 292. Brazil Bradykinin Receptor Antagonists Market Size, by Indication, 2017-2032 (USD Million)
TABLE 293. Brazil Bradykinin Receptor Antagonists Market Size, by Chronic Cough, 2017-2032 (USD Million)
TABLE 294. Brazil Bradykinin Receptor Antagonists Market Size, by Hereditary Angioedema, 2017-2032 (USD Million)
TABLE 295. Brazil Bradykinin Receptor Antagonists Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 296. Brazil Bradykinin Receptor Antagonists Market Size, by Oral, 2017-2032 (USD Million)
TABLE 297. Brazil Bradykinin Receptor Antagonists Market Size, by Parenteral, 2017-2032 (USD Million)
TABLE 298. Brazil Bradykinin Receptor Antagonists Market Size, by End User, 2017-2032 (USD Million)
TABLE 299. Brazil Bradykinin Receptor Antagonists Market Size, by Ambulatory Care, 2017-2032 (USD Million)
TABLE 300. Brazil Bradykinin Receptor Antagonists Market Size, by Home Care, 2017-2032 (USD Million)
TABLE 301. Brazil Bradykinin Receptor Antagonists Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 302. United Kingdom Bradykinin Receptor Antagonists Market Size, 2017-2032 (USD Million)
TABLE 303. United Kingdom Bradykinin Receptor Antagonists Market Size, by Type, 2017-2032 (USD Million)
TABLE 304. United Kingdom Bradykinin Receptor Antagonists Market Size, by Biologic, 2017-2032 (USD Million)
TABLE 305. United Kingdom Bradykinin Receptor Antagonists Market Size, by Indication, 2017-2032 (USD Million)
TABLE 306. United Kingdom Bradykinin Receptor Antagonists Market Size, by Chronic Cough, 2017-2032 (USD Million)
TABLE 307. United Kingdom Bradykinin Receptor Antagonists Market Size, by Hereditary Angioedema, 2017-2032 (USD Million)
TABLE 308. United Kingdom Bradykinin Receptor Antagonists Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 309. United Kingdom Bradykinin Receptor Antagonists Market Size, by Oral, 2017-2032 (USD Million)
TABLE 310. United Kingdom Bradykinin Receptor Antagonists Market Size, by Parenteral, 2017-2032 (USD Million)
TABLE 311. United Kingdom Bradykinin Receptor Antagonists Market Size, by End User, 2017-2032 (USD Million)
TABLE 312. United Kingdom Bradykinin Receptor Antagonists Market Size, by Ambulatory Care, 2017-2032 (USD Million)
TABLE 313. United Kingdom Bradykinin Receptor Antagonists Market Size, by Home Care, 2017-2032 (USD Million)
TABLE 314. United Kingdom Bradykinin Receptor Antagonists Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 315. Germany Bradykinin Receptor Antagonists Market Size, 2017-2032 (USD Million)
TABLE 316. Germany Bradykinin Receptor Antagonists Market Size, by Type, 2017-2032 (USD Million)
TABLE 317. Germany Bradykinin Receptor Antagonists Market Size, by Biologic, 2017-2032 (USD Million)
TABLE 318. Germany Bradykinin Receptor Antagonists Market Size, by Indication, 2017-2032 (USD Million)
TABLE 319. Germany Bradykinin Receptor Antagonists Market Size, by Chronic Cough, 2017-2032 (USD Million)
TABLE 320. Germany Bradykinin Receptor Antagonists Market Size, by Hereditary Angioedema, 2017-2032 (USD Million)
TABLE 321. Germany Bradykinin Receptor Antagonists Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 322. Germany Bradykinin Receptor Antagonists Market Size, by Oral, 2017-2032 (USD Million)
TABLE 323. Germany Bradykinin Receptor Antagonists Market Size, by Parenteral, 2017-2032 (USD Million)
TABLE 324. Germany Bradykinin Receptor Antagonists Market Size, by End User, 2017-2032 (USD Million)
TABLE 325. Germany Bradykinin Receptor Antagonists Market Size, by Ambulatory Care, 2017-2032 (USD Million)
TABLE 326. Germany Bradykinin Receptor Antagonists Market Size, by Home Care, 2017-2032 (USD Million)
TABLE 327. Germany Bradykinin Receptor Antagonists Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 328. France Bradykinin Receptor Antagonists Market Size, 2017-2032 (USD Million)
TABLE 329. France Bradykinin Receptor Antagonists Market Size, by Type, 2017-2032 (USD Million)
TABLE 330. France Bradykinin Receptor Antagonists Market Size, by Biologic, 2017-2032 (USD Million)
TABLE 331. France Bradykinin Receptor Antagonists Market Size, by Indication, 2017-2032 (USD Million)
TABLE 332. France Bradykinin Receptor Antagonists Market Size, by Chronic Cough, 2017-2032 (USD Million)
TABLE 333. France Bradykinin Receptor Antagonists Market Size, by Hereditary Angioedema, 2017-2032 (USD Million)
TABLE 334. France Bradykinin Receptor Antagonists Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 335. France Bradykinin Receptor Antagonists Market Size, by Oral, 2017-2032 (USD Million)
TABLE 336. France Bradykinin Receptor Antagonists Market Size, by Parenteral, 2017-2032 (USD Million)
TABLE 337. France Bradykinin Receptor Antagonists Market Size, by End User, 20

Companies Mentioned

  • Abbott Laboratories
  • Bayer AG
  • BioCryst Pharmaceuticals, Inc.
  • Boehringer Ingelheim International GmbH
  • CSL Limited
  • Dyax Corp.
  • Elan Pharmaceuticals, Inc.
  • Ionis Pharmaceuticals, Inc.
  • Jerini AG
  • KalVista Pharmaceuticals, Inc.
  • Laboratoires Fournier S.A.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Pharming Group N.V.
  • Pharvaris N.V.
  • Sanofi S.A.
  • SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A.
  • Swedish Orphan Biovitrum AB
  • Takeda Pharmaceutical Company Limited

Related Topics

Related Reports

Drugs for Conn's Syndrome Market - Global Forecast 2026-2032 - Product Image

Drugs for Conn's Syndrome Market - Global Forecast 2026-2032

  • Report
  • 186 Pages
  • Global
From
aIIbß3 Antagonists Market - Global Forecast 2026-2032 - Product Image

aIIbß3 Antagonists Market - Global Forecast 2026-2032

  • Report
  • 193 Pages
  • Global
From
Neuroregeneration Therapy Market - Global Strategic Business Report - Product Image

Neuroregeneration Therapy Market - Global Strategic Business Report

  • Report
  • 480 Pages
  • Global
From
Medications for Heart Failure Market Report 2026 - Product Image

Medications for Heart Failure Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Histatrol Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts - Product Image

Histatrol Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

  • Report
  • 250 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.